This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

27 Dec 2011

Covis Acquires Rights to Certain GSK Drugs in US and Puerto Rico

Covis Pharma has acquired rights to GSK’s drug products in the US and Puerto Rico.

Switzerland-based specialty pharmaceutical company Covis Pharma has acquired full commercial rights to GlaxoSmithKline’s Fortaz (ceftazidime), Zinacef (cefuroxime), Lanoxin (digoxin), Parnate (tranylcypromine sulfate), and Zantac Injection (ranitidine hydrochloride) in the US and Puerto Rico.


GSK will retain the existing rights for these products in countries outside the US.


"Our management team looks forward to building out our platform beyond the current focus on the acute care, cardiovascular and CNS markets, into new and adjacent therapeutic areas", said Jack Davis, chief executive of Covis Pharma.


Covis Pharmaceuticals Inc

Related News